�ImmuneRegen� BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), announced that in a controlled study performed on Yorkshire pigs, its wound-healing drug prospect, Homspera�, has accelerated the healing process of rich, dermal excisions. ImmuneRegen performed the in vivo study with Bio-Quant, Inc., a biotechnology exploitation company that also provides contracted preclinical research services. The study results add to the body of evidence of Homspera's power to get wound healing and farther support the potential application of Homspera in diverse areas such as thermal and chemical burns, field of honor trauma, and wounds such as diabetic and air pressure ulcers, as well as surgical and traumatic wounds.
Bio-Quant performed the 24-day study on Yorkshire pigs, which have similar hide and wound-healing mechanisms as humans and are therefore a favorite model for wound-healing studies. Four sets of four wounds on each of two pigs were treated with dissimilar concentrations of Homspera and compared with a four-wound control lay out. Homspera's healing effect was pronounced on both the size of the injury and its rate of closure. The excisions were made through the full thickness of the dermic layers, and then topically treated with Homspera. Homspera stimulated the deposition of collagen, which is the main protein in the body's connection tissue, by increasing the accumulation of fibroblasts, the cells that produce collagen. Homspera rock-bottom wound size of it an average of 21 percent over the control at Day 10, 27 percent at Day 14, and 36 percent at Day 21. Additional research, studies and testing of Homspera volition be compulsory to gratify FDA and other applicable laws and regulations before any conclusions can be made around the manipulation of Homspera for future product development or for human therapeutical treatment.
"Homspera reduces the wound area of full-thickness excisional wounds, likely by increasing fibroblast proliferation and collagen deductive reasoning and dethronement throughout the proliferative and remodeling stages of lesion repair," explained Hal Siegel, Ph.D., ImmuneRegen VP and chief scientific officer. "In fact, Homspera may accelerate all phases of wound closure, peradventure stimulating the earliest stages via the hematopoietic base cell activeness previously described."
Said Michael K. Wilhelm, ImmuneRegen chairman and CEO, "From the results of our versatile studies, Homspera continues to show noteworthy versatility as a stand-alone therapeutic. We are development a numeral of formulations for unmilitary and military uses, such as the spray-on lotion we ar exploring with BioCure, Inc. and the topical gelatin application we are exploring with DelSite, that we believe will strengthen our position for out-licensing and/or expedited product development for Homspera."
About Bio-Quant, Inc.
Bio-Quant, Inc. is a revenue-generating biotechnology company located in San Diego, Calif., focused on developing proprietorship biopharmaceutical drug candidates in the areas of oncology, and microbial and immunologic diseases, as well as providing contract preclinical development and drug discovery services to other biopharmaceutical companies. Bio-Quant has several compounds in assorted stages of preclinical development, as well as relationships with several major biopharmaceutical companies for its services business. Bio-Quant applies its expertise in immunology and oncology toward developing biopharmaceuticals to fight diseases such as mastermind and colon cancers, lymphoma, leukemia, vitiligo and cirrhosis. For more information, please visit hTTP://www.bio-quant.com.
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences, Inc., a completely owned underling of IR BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage biotechnology company focused on the research, development and licensing of Homspera�, an adult prow cell fighting compound that in study results has been shown to rectify and fortify the resistant system and enhance wound healing. To advance its mission, the Scottsdale, Arizona, based company has bad numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, Lovelace Respiratory Research Institute, HemoGenix and Virion Systems, Inc. http://www.immuneregen.com
Statements about ImmuneRegen's future expectations, including statements about the potential role and scientific results for ImmuneRegen's do drugs candidates, science and engineering, and all other statements in this press release other than historical facts, are "modern statements" inside the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such modern statements be subject to the dependable harbors created thereby. These future events may non occur as and when expected, if at all, and, together with ImmuneRegen's business, ar subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a solution of a number of factors, including the fact that results of the studies involved only a small number of Yorkshire pigs, the studies were limited in scope, the uncertainties inbuilt in research and exploitation collaborations, presymptomatic and clinical trials and product development programs (including, but non limited to the fact that future results or research and development efforts may prove less supporting than electric current results or cause side effects non observed in current preclinical trials), the evaluation of potential opportunities, the stratum of bodied expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the threesome months ended March 31, 2008, and on Form 10-KSB for the year ended December 31, 2007, as filed with the Securities and Exchange Commission. There are no guarantees that whatsoever of ImmuneRegen's proposed products will test to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements.
ImmuneRegen BioSciences, Inc.
More info
